Zobrazeno 1 - 10
of 87
pro vyhledávání: ''
Publikováno v:
Cellular Oncology (2211-3428). Feb2016, Vol. 39 Issue 1, p89-95. 7p.
Autor:
Singh, Kamaljeet, He, Xin, Kalife, Elizabeth T., Ehdaivand, Shahrzad, Wang, Yihong, Sung, C. James
Publikováno v:
Breast Cancer Research & Treatment; Feb2018, Vol. 168 Issue 1, p29-34, 6p
Publikováno v:
Medical Oncology; Jun2003, Vol. 20 Issue 2, p127-136, 10p
Autor:
Arja Jukkola-Vuorinen, Anniina Jääskeläinen, Kirsi-Maria Haapasaari, Päivi Auvinen, Ylermi Soini, Peeter Karihtala
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background: The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0882fc6ea4b5d717997d116945eea4b4
http://urn.fi/urn:nbn:fi-fe201804196713
http://urn.fi/urn:nbn:fi-fe201804196713
Autor:
McCarthy, Nicola
Publikováno v:
Nature Reviews Cancer. Jun2013, Vol. 13 Issue 6, p378-378. 1p.
Autor:
Fabio Corradini, Francesco Piva, Riccardo Cellerino, C. Brugiati, R. Bracci, Eva Galizia, Italo Bearzi, Alessandra Viel, L. Belvederesi, Diana Baralle, Francesca Bianchi, Michela Raponi, Cristian Loretelli
Publikováno v:
Familial Cancer
Single base substitutions can lead to missense mutations, silent mutations or intronic mutations, whose significance is uncertain. Aberrant splicing can occur due to mutations that disrupt or create canonical splice sites or splicing regulatory seque
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Publikováno v:
BMC Cancer
Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial c
Autor:
Claire Josse, Vincent Bours, Pierre Frères, Guy Jerusalem, Bouchra Boujemla, Stephane Wenric, Karin Segers, Raphaël Marée, Joëlle Collignon, Meriem Boukerroucha, Sonia ElGuendi
Publikováno v:
BMC Cancer
Background The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can be lost by multiple mechanisms: germinal mutation followed by deletion of the second allele; negative regulation by promoter methylation
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho